PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
119.51
Positive P/E while Drug Manufacturers - Specialty & Generic median is negative at -0.20. Peter Lynch would investigate competitive advantages in a distressed Drug Manufacturers - Specialty & Generic.
1208.41
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.33. Jim Chanos would check for potential multiple compression risks.
14.73
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.31. Jim Chanos would check for potential asset write-down risks.
-468.55
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -1.34. Seth Klarman would investigate cash flow improvement potential.
-17032.97
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
14.73
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.32. Jim Chanos would check for valuation bubble risks.
0.21%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-0.21%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.07%. Seth Klarman would investigate cash flow improvement potential.